ABLYNX INITIATES A MULTINATIONAL PHASE III STUDY WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED TTP, A RARE BLOOD CLOTTING DISORDER
September 29, 2015 01:04 ET
|
Ablynx
Caplacizumab is a first-in-class anti-von Willebrand factor (vWF) Nanobody® in development for the treatment of acquired thrombotic thrombocytopenic purpura (TTP)
Acquired TTP is an...
ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2015
August 27, 2015 01:06 ET
|
Ablynx
REGULATED INFORMATION
Caplacizumab on track to enter Phase III in acquired TTP, with Ablynx committed to lead commercialisation in Europe and the USA
4 Phase II clinical programmes...
ABLYNX TO HOST WEBCAST FOR ITS 2015 HALF-YEAR RESULTS ON 27 AUGUST
August 19, 2015 01:04 ET
|
Ablynx
GHENT, Belgium, Aug. 19, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will announce its half-year results for 2015 on Thursday 27 August 2015 at 7.00 am CET.
The Ablynx...
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
August 14, 2015 01:10 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, Aug. 14, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...
ABLYNX INITIATES PHASE II SLE STUDY WITH ITS ANTI-IL-6R NANOBODY, PARTNERED WITH ABBVIE
August 04, 2015 01:06 ET
|
Ablynx
GHENT, Belgium, Aug. 4, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has administered the first dose in the Phase II STEADY study to evaluate the...
ABLYNX ANNOUNCES WARRANT EXERCISE
July 31, 2015 01:05 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, July 31, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the...
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
July 29, 2015 01:05 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, July 29, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...
ABLYNX SIGNIFICANTLY EXPANDS ITS IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC.
July 22, 2015 01:08 ET
|
Ablynx
Builds on the original immuno-oncology collaboration started in 2014, significantly expanding the size and scope of the deal to include up to 12 additional Nanobody programmes
Expanded deal...
ABLYNX ANNOUNCES WARRANT EXERCISE
July 20, 2015 01:04 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, July 20, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the...
OPPENHEIMER FUNDS, INC. ANNOUNCE 3.07% SHAREHOLDING IN ABLYNX
July 14, 2015 01:11 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, July 14, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...